Codagenix's Nasal COVID 19 Vaccine

 Codagenix's Nasal COVID 19 Vaccine

👉Serum Institute of India , the world's largest vaccine maker by number of doses produced, has started manufacturing COVID 19 Vaccine candidate developed by Codagenix INc, the US biotech firm.

👉Codagenix's COVID19 vaccine is delivered by intra nasally rather than via an injection, Robert Coleman, Ph.d,CEO of Codagenix said

👉This vaccine is also known as CDX-005, it has completed pre clinical animal studies.

👉The company aims to initiate Phase 1 clinical trial of its COVID 19 vaccine in the UK by the end of this year.

👉The biotech company said in a statement, "Pre clinical testing of a single intranasal dose of CDX-005 in animals has yielded encouraging safety and efficacy signals." With serum institute's financial and technical support, we expect to rapidly propel the vaccine into the clinical before the end of 2020" Coleman added.

Working Mechanism of Vaccine and How it different from other vaccine ?

👉Coleman said, "CDX-005 was engineered using our proprietary codon deoptimization software platform, which allowed us to recode the genome of the SARS-CoV-2 virus by inserting hundreds of mutations. These mutations result in a live attenuated vaccine that is non pathogenic yet has the potential to stimulate a robust T cell and antibody immune response that mimics that of the wild type virus. Our live attenuated vaccine approach is in sharp contrast to many of the more common COVID 19 immunization strategies currently undergoing human testing such as mRNA or Virus like particle candidate, which only target the spike protein or the adnovirus vectored approaches that could cause off target effects"

👉Serum institute received regulatory approval from the Review Committee on Genetic Manipulation of India's department of Biotechnology for manufacturing Codagenix's COVID 19 vaccine.